Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|15|9|792-802

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.15, Iss.9, 2015-11, pp. : 792-802

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of gefitinib in the management of Asian patients with non-small cell lung cancer

By Chang Alex Y  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 401-411

Informa Healthcare

Access to resources Recommend Favorite

Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 12, Iss. 3, 2012-03 ,pp. : 237-246

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer

By Stinchcombe Thomas E.   Socinski Mark A.  

Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. : 321-332

Adis International

Access to resources Recommend Favorite